Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro

Ji Hyun Jang; Sang Hak Lee; Jin Hyoung Kang; Hee Sik Sun; Kazuto Nishio; Nagahiro Saijo; Hyo Jeong Kuh

doi:10.4143/crt.2002.34.5.372

Articles

Page Path: HOME > Cancer Res Treat > Volume 34(5); 2002 > Article

Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro: Ji Hyun Jang, Sang Hak Lee, Jin Hyoung Kang, Hee Sik Sun, Kazuto Nishio, Nagahiro Saijo, Hyo Jeong Kuh; Cancer Research and Treatment 2002;34(5): 372-381.
DOI: https://doi.org/10.4143/crt.2002.34.5.372
Published online: October 31, 2002

¹Catholic Research Institutes of Medical Science, CatholicUniversity of Korea, Seoul, Korea. hkuh@catholic.ac.kr
²Division of Medical Oncology, Catholic University of Korea,Seoul, Korea.
³Division of Gastroenterology, Catholic University of Korea,Seoul, Korea.
⁴Pharmacology Division, National Cancer Center ResearchInstitute, Tokyo, Japan.

5,816 Views
39 Download
3 Crossref
0 Scopus

prev next

Full Article

Download PDF

Abstract

PURPOSE
Oxaliplatin (LOHP), 5-FU, and paclitaxel (PTX) are considered highly active against advanced gastric carcinomas, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, ZD1839 is considered as a good candidate for the treatment of gastric cancers when given alone or in combination with cytotoxic agents. The present study evaluated the antitumor effects of these agents in SNU-1 human gastric cancer cells either alone or when given as a doublet (i.e., as a cytotoxic-cytostatic combination).
MATERIALS AND METHODS
We selected SNU-1 cells that showed DNA mismatch repair (MMR) deficiency and EGFR overexpression. Growth inhibition was measured by MTT and by direct cell counting and cell cycle distribution by flow cytometry. The combination index (CI) was used to describe synergistic interaction.
RESULTS
The four drugs showed IC50s ranging from 1.81 nM to 13.2microM. MTT assay appeared to underestimate the cytotoxicity of PTX, which was attributed to a significant resistant fraction (32%). LOHP and PTX induced G2/M arrest, 5-FU increased in S phase, and ZD1839 in-creased in G1 in a concentration dependent manner. PTX ZD1839 showed the greatest synergism and LOHP ZD1839 showed a similar result. The cell cycle effect of PTX was potentiated by the coadministration of ZD1839. A previously developed cytostatic TPi model was used to assess the contribution of cell cycle arrest to overall growth inhibition, and 64% and 80% of the overall growth inhibition was attributed to cell cycle arrest for LOHP and PTX, when exposed to 7.55microM and 10 nM for 72 hr, respectively.
CONCLUSION
This study demonstrates the antitumor activity and significant cell cycle arrest effect of ZD1839 against human gastric carcinoma cells and its synergistic interaction with LOHP and PTX. These results provide a preclinical rationale for the clinical development of ZD1839 and its use in combination with LOHP or PTX against human gastric cancers that express EGFR.

Keywords: Oxaliplatin;5-FU;Paclitaxel;ZD1839;Combination;Human gastric carcinoma

Figure & Data

References

Citations

Citations to this article as recorded by

An efficient and flexible framework for inferring global sensitivity of agent-based model parameters
Daniel R. Bergman, Trachette Jackson, Harsh Vardhan Jain, Kerri-Ann Norton, Nicholas Geard
PLOS Computational Biology.2025; 21(9): e1013427. CrossRef
Connecting Agent-Based Models with High-Dimensional Parameter Spaces to Multidimensional Data Using SMoRe ParS: A Surrogate Modeling Approach
Daniel R. Bergman, Kerri-Ann Norton, Harsh Vardhan Jain, Trachette Jackson
Bulletin of Mathematical Biology.2024;[Epub] CrossRef
A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study
Marisa C. Eisenberg, Harsh V. Jain
Journal of Theoretical Biology.2017; 431: 63. CrossRef

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro

Cancer Res Treat. 2002;34(5):372-381. Published online October 31, 2002

DOI: https://doi.org/10.4143/crt.2002.34.5.372